株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

神経変性疾患の新しい治療薬:パートI - アルツハイマー病・パーキンソン病の新しい標的治療薬戦略技術

Emerging Therapeutics for Neurodegenerative Diseases, Part I: Novel Targeted Therapeutic Strategies Technologies for Alzheimer's and Parkinson's Diseases

発行 Frost & Sullivan 商品コード 910112
出版日 ページ情報 英文 110 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.55円で換算しております。
Back to Top
神経変性疾患の新しい治療薬:パートI - アルツハイマー病・パーキンソン病の新しい標的治療薬戦略技術 Emerging Therapeutics for Neurodegenerative Diseases, Part I: Novel Targeted Therapeutic Strategies Technologies for Alzheimer's and Parkinson's Diseases
出版日: 2019年08月23日 ページ情報: 英文 110 Pages
概要

当レポートでは、アルツハイマー病およびパーキンソン病の新しい治療薬の動向を調査し、疾患の背景・概要、新しい治療薬の種類・概要、薬剤開発の現況・課題、市場の潜在性、企業および企業間の取り組み、市場への各種影響因子の分析などをまとめています。

第1章 エグゼクティブサマリー

第2章 神経変性疾患:技術環境・動向

  • 現状・課題
  • 多因子発症
  • 同時トリガー因子
  • 新興治療薬
  • 補完医療

第3章 神経変性の新しい治療

  • 治療・診断ソリューション:PROTAC
  • 神経変性治療:標的タンパク質リガンド
  • 治療・診断ソリューション:ペプトイド
  • 神経変性治療:ペプトイドアプローチ
  • 神経変性治療:凝集阻害剤
  • 神経変性治療:細胞シグナル伝達モジュレーター
  • 神経変性治療:バイオミメティック神経保護剤
  • 神経変性治療:炎症調節剤
  • 神経変性治療:画像診断用バイオマーカー
  • 神経変性治療:ペプトイドインターベンション
  • 治療・診断ソリューション:幹細胞/遺伝子療法
  • 神経変性治療:細胞療法の開発
  • 治療・診断ソリューション:腸内微生物叢
  • 神経変性治療:腸内微生物叢のインターベンション
  • 治療・診断ソリューション:ナノテクノロジー・プロドラッグ・コドラッグ
  • 治療・診断ソリューション:カンナビジオール
  • 神経変性治療:予防・管理

第4章 技術の現況:レビュー・評価

  • 神経変性前臨床モデル:ニーズと複雑性
  • 神経変性モデルの欠点:アルツハイマー病
  • 神経変性モデルの欠点:パーキンソン病
  • 治療技術の現況
  • アルツハイマー病治療薬の開発状況
  • パーキンソン病治療薬の開発状況

第5章 技術レーダーインテリジェントソリューション

  • 緩和治療から将来戦略へ
  • 新しい治療戦略・予備的成果
  • 臨床試験の進むモノクローナル抗体
  • オートファジーを強化する薬理学的製剤
  • アルツハイマー病:有望な候補分子薬
  • パーキンソン病:主要企業

第6章 市場潜在性・技術導入

  • 神経変性疾患市場の潜在性
  • 総合的環境への影響因子
  • 産業提携:SWOT分析
  • 神経変性疾患の協力的枠組み
  • 概要:事業提携・技術能力
  • 提携イニチアチブによる標的

第7章 事業環境・知的財産権

  • 事業開発への実用的影響
  • 事業・プロセスへの影響
  • 技術移転評価

第8章 付録

  • 薬剤パイプライン:アルツハイマー病
  • 薬剤パイプライン:パーキンソン病

第9章 コンタクト情報

  • 主な産業インフルエンサー
  • 免責事項
目次
Product Code: D8BB

Novel Targeted Therapeutic Strategies Technologies Around Neurodegenerative Disorders - From Palliative to Future Interventions

At present, only a few therapies are available with relatively low success. Both, the clinical and the scientific communities are critically devoted to develop new therapeutic approaches to treat and diagnose neurodegenerative diseases.

At present days, neurodegenerative diseases represent one of the main causes of death in the industrialized economy. Overall characterized by a loss of neurons in particular regions of the nervous system, the subsequent decline in cognitive and motor function that patients experience in these diseases is associated with nerve cell loss.

The most common denominator among neurodegenerative diseases, in addition to nerve cell loss is inflammation. Although, a series of mutant genes and environmental toxins are related to neurodegenerative disorders, the causal mechanisms remain poorly understood.

Neurodegenerative diseases can be defined as multifactorial debilitating disorders of the nervous system. Overall, neurodegenerative diseases affect approximately 30 million individuals worldwide, according to the World Health Organization (WHO).

Factors Contributing to Neurodegenerative Diseases

The factors contributing to the onset of neurodegenerative diseases are multiple. Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS) diseases are well-established as the consequence of misfolding and dysfunctional trafficking of proteins. However, other factors including mitochondrial dysfunction, oxidative stress, aging, and environmental issues are deeply associated with the onset of neurodegeneration.

Molecular Mechanisms Underlying Neurodegeneration

Although all these factors have been demonstrated to significantly contribute to the etiology of common neurodegenerative diseases, some molecular mechanisms underlying neurodegeneration remain unveiled.

Present efforts are focused on the identification of viable drug targets and biomarkers for early diagnosis of the diseases, in order to develop the best suited therapies.

  • Some Multifactorial Conditions to Watch
  • Abnormal protein dynamics
  • Defective protein degradation and aggregation
  • Oxidative stress
  • Free radical formation
  • Impaired bioenergetics
  • Mitochondrial dysfunction
  • Exposure to toxic metals and pesticides
  • Others
  • Coverage of Neurodegenerative Diseases Technologies

This research service, ‘Emerging Therapeutics for Neurodegenerative Diseases', focuses on the leading technology and business trends that are making possible the implementation of cutting-edge innovations that help to face the present and future challenges of the neurodegenerative disease therapeutics sector.

The tendencies depicted in this study will help to drive the sustainability of the neurodegenerative disease therapeutics industry by directly exhibiting the principal challenges faced by leading biopharmaceutical and biotechnology companies to develop new product modalities in an affordable and high performance style, while getting market acceptance and achieving market leadership by translating technology innovation to market competitiveness

The study covers the following topics:

  • Technology roadmap, trends, capabilities, and applications targeted
  • Stakeholder activities, influence, industry initiatives, investment environment, and funding support
  • Regional and global regulation landscape and standardization approaches for tackling challenges
  • Technology benchmarking for smart decisions

An appendix is included, comprising lists of major industry influencers found in the field.

Table of Contents

1.0. Executive Summary

  • 1.1. Facts and Findings: Neurodegenerative Diseases
  • 1.2. Research Focus: Neurodegenerative Diseases
  • 1.3. Research Scope: Foreseeing Challenges and Solutions
  • 1.4. Analysis Framework: Frost & Sullivan's Core Value
  • 1.5. Research Methodology

2.0. Technology Landscape and Trends

  • 2.1. Neurodegenerative Diseases: Facts and Challenges
  • 2.2. Neurodegenerative Diseases: Multifactorial Onset
  • 2.3. Neurodegenerative Diseases: Concurrent Triggering Factors
  • 2.4. Neurodegenerative Diseases: Emerging Therapies
  • 2.5. Neurodegenerative Diseases: Complementary Therapies

3.0. Emerging Therapies to Address Neurodegeneration

  • 3.1. Therapeutic and Diagnostic Solutions: PROTACs
  • 3.2. Neurodegenerative Therapies: Targeting Protein Ligands
  • 3.3. Therapeutic and Diagnostic Solutions: Peptoids
  • 3.4. Neurodegenerative Therapies: Five Peptoid Approaches
  • 3.5. Neurodegenerative Therapies: Aggregation Inhibitors
  • 3.6. Neurodegenerative Therapies: Cell Signaling Modulators
  • 3.7. Neurodegenerative Therapies: Biomimetic Neuroprotectors
  • 3.8. Neurodegenerative Therapies: Inflammation Regulators
  • 3.9. Neurodegenerative Therapies: Imaging Diagnostics Biomarkers
  • 3.10. Neurodegenerative Therapies: Summary of Peptoid Interventions
  • 3.11. Therapeutic and Diagnostic Solutions: Stem Cell/Gene Therapies
  • 3.12. Neurodegenerative Therapies: Cell Therapy Developments
  • 3.13. Therapeutic and Diagnostic Solutions: Gut Microbiome
  • 3.14. Neurodegenerative Therapies: Gut Microbiome Interventions
  • 3.15. Therapeutic and Diagnostic Solutions: Nanotech, Prodrug, and Codrug
  • 3.16. Therapeutic and Diagnostic Solutions: Cannabidiols
  • 3.17. Neurodegenerative Therapies: Prevention and Management

4.0. Technology Status Review and Assessment

  • 4.1. Neurodegenerative Preclinical Models: Needs and Complexities
  • 4.2. Neurodegenerative Models' Pitfalls: Alzheimer's Disease
  • 4.3. Neurodegenerative Models' Pitfalls: Parkinson's Disease
  • 4.4. Present Status of Therapeutics Technology
  • 4.5. Alzheimer's Disease Drug Development Status
  • 4.5. Alzheimer's Disease Drug Development Status (continued)
  • 4.5. Alzheimer's Disease Drug Development Status (continued)
  • 4.5. Alzheimer's Disease Drug Development Status (continued)
  • 4.5. Alzheimer's Disease Drug Development Status (continued)
  • 4.6. Parkinson's Disease Drug Development Status

5.0. Technology Radar Intelligent Solutions

  • 5.1. From Palliative Treatment to Future Strategies
  • 5.2. New Treatment Strategies and Preliminary Outcomes
  • 5.2. New Treatment Strategies and Preliminary Outcomes (continued)
  • 5.3. Monoclonal Antibodies Advancing Clinical Trials
  • 5.4. Pharmacological Agents Enhancing Autophagy
  • 5.5. Top Promising Candidates for Alzheimer's Disease
  • 5.6. Parkinson's Disease Top Companies

6.0. Market Potential and Technology Adoption

  • 6.1. Neurodegenerative Diseases Market Potential
  • 6.2. Overall Environmental Impact Factors
  • 6.3. Best-fit Industry Partnerships: SWOT Analysis
  • 6.4. Collaborative Framework for Neurodegenerative Diseases
  • 6.5. Overview of Business Partnerships and Technology Capabilities
  • 6.6. Key Aspects to Target through Collaborative Initiatives

7.0. Business Landscape and Intellectual Property Analysis

  • 7.1. Actionable Impact on Business Development
  • 7.2. Repercussions on Businesses and Processes
  • 7.3. Technology Transfer Assessment

8.0. Appendix

  • 8.1. Alzheimer's Disease Drug Pipeline
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.2. Parkinson's Disease Drug Pipeline
  • 8.2. Parkinson's Disease Drug Pipeline (continued)

9.0. Key Industry Contacts

  • 9.1. Key Industry Influencers
  • 9.1. Key Industry Influencers (continued)
  • 9.1. Key Industry Influencers (continued)
  • 9.1. Key Industry Influencers (continued)
  • 9.1. Key Industry Influencers (continued)
  • Legal Disclaimer
Back to Top